TheStreet: Alkermes should stick to drug delivery

Alkermes ($ALKS) is among the industry's most successful drug delivery firms, boasting licensing deals and royalty streams with drugmakers around the world, in addition to a few in-house treatments in the pipeline. Why, then, has its stock price stayed largely flat? In TheStreet, Nathan Sadeghi-Nejad writes that the company needs to build on its success in drug delivery, perhaps through timely acquisitions of smaller firms. Analysis

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.